Different associations between organ-specific immune-related adverse event and survival in non-small cell lung cancer patients treated with programmed death-1 inhibitors-based combination therapy.
Journal Information
Full Title: Ther Adv Med Oncol
Abbreviation: Ther Adv Med Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"The authors declare that there is no conflict of interest."
Funding Disclosure
Evidence found in paper:
"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the grants from the National Natural Science Foundation of China (Grant No. 82073211, 81702892, 82002434, 82003106); Jiangsu Province Capability Improvement Project through Science, Technology and Education, Jiangsu Provincial Medical Key Laboratory (ZDXYS202203); and Jiangsu Provincial Medical Innovation Center (CXZX202224)."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025